100%. Everything in this announcement is positive, other than the loss of one patient which is recognised that they had the more aggressive type of MND, AND was on the weakest trial doses the whole time. The Ph1 data showed how well the 10 mg/kg cohort responded to MPL, which of course is what PAA are moving forward with in the OLE & the Ph2.
Ann: Appendix 4C & Quarterly Update, page-18
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $94.89M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $58.40K | 305.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 115000 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 86074 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |